Bliss GVS Pharma Reports Mixed Financial Results with Significant Growth and Rising Costs in June 2025

Bliss GVS Pharma has recently reported its financial results for the quarter ending June 2025, revealing a notable shift in its evaluation. The company's score has seen an adjustment, moving to a neutral position from a previous lower assessment over the last three months. The financial data indicates several positive trends for Bliss GVS Pharma. The Profit After Tax (PAT) for the quarter stands at Rs 43.04 crore, reflecting a significant year-on-year growth of 107.9%. Additionally, the company has achieved its highest operating profit margin in the last five quarters at 19.92%, showcasing improved operational efficiency. The Earnings per Share (EPS) has also reached a peak of Rs 4.08, indicating enhanced profitability for shareholders. However, there are areas of concern as well. The interest expense has surged to Rs 5.47 crore, marking a substantial quarter-on-quarter increase of 225.60%. This rise in interest costs suggests an uptick in borrowings, which may impact the company's financial stability. Furthermore, the Debtors Turnover Ratio has declined to its lowest point in recent periods, indicating a slowdown in the pace of settling debts. Overall, Bliss GVS Pharma's latest financial results present a mixed picture, with both positive developments and challenges that warrant attention. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.